{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:00:33Z","timestamp":1787868033741,"version":"build-2784847793"},"reference-count":132,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The potential of nanotechnology in advancing the diagnosis and treatment of neurodegenerative\ndiseases is explored in this comprehensive literature review. The findings of these studies\nsuggest that nanotechnology has the capacity to improve existing therapeutic approaches, create\nnovel and safe compounds, and develop more precise imaging techniques and diagnostic methods\nfor neurodegenerative diseases. With the emergence of the nanomedicine era, a new and innovative\napproach of diagnosing and treating these conditions has been introduced. Notably, the researchers'\ndevelopment of a nanocarrier drug delivery tool demonstrates immense potential compared to\nconventional therapy, as it maximizes therapeutic efficacy and minimizes undesirable as side\neffects.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0118715273297024240201055550","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T07:25:56Z","timestamp":1707895556000},"page":"1251-1262","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Designing and Formulation of Nanocarriers for \u201cAlzheimer\u2019s and\nParkinson\u2019s\u201d Early Detection and Therapy"],"prefix":"10.2174","volume":"23","author":[{"given":"Jakleen","family":"Abujamai","sequence":"first","affiliation":[{"name":"Medicine Program, Batterjee Medical College, Jeddah 21442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukhsana","family":"Satar","sequence":"additional","affiliation":[{"name":"Division of Biochemistry, Department\nof Physiology and Biochemistry, Ibn Sina National College for Medical Studies, Jeddah 22421, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-8034","authenticated-orcid":true,"given":"Shakeel Ahmed","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medicine Program, Batterjee Medical College, Jeddah 21442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.arabjc.2017.05.011","volume":"12","author":"Khan I.","year":"2019","unstructured":"Khan I.; Saeed K.; Khan I.; Nanoparticles: Properties, applications and toxicities. Arab J Chem  2019,12(7),908-931","journal-title":"Arab J Chem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3892\/br.2021.1418","volume":"14","author":"Sim S.","year":"2021","unstructured":"Sim S.; Wong N.; Nanotechnology and its use in imaging and drug delivery (Review). Biomed Rep  2021,14(5),42-51","journal-title":"Biomed Rep"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"Patra J.K.","year":"2018","unstructured":"Patra J.K.; Das G.; Fraceto L.F.; Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnol  2018,16(1),71-77","journal-title":"J Nanobiotechnol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3390\/polym15071596","volume":"15","author":"Yusuf A.","year":"2023","unstructured":"Yusuf A.; Almotairy A.R.Z.; Henidi H.; Alshehri O.Y.; Aldughaim M.S.; Nanoparticles as drug delivery systems: A review of the implication of nanoparticles\u2019 physicochemical properties on responses in biological systems. Polymers  2023,15(7),1596-1603","journal-title":"Polymers"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2147\/IJN.S121956","volume":"12","author":"Wang L.","year":"2017","unstructured":"Wang L.; Hu C.; Shao L.; The antimicrobial activity of nanoparticles: Present situation and prospects for the future. Int J Nanomed  2017,12,1227-1249","journal-title":"Int J Nanomed"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"112111","DOI":"10.1016\/j.eurpolymj.2023.112111","volume":"193","author":"Ahamed J.","year":"2023","unstructured":"Ahamed J.; Jaswanth Gowda B.H.; Almalki W.H.; Gupta N.; Sahebkar A.; Kesharwani P.; Recent advances in nanoparticle-based approaches for the treatment of brain tumors: Opportunities and challenges. Eur Polym J  2023,193,112111","journal-title":"Eur Polym J"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"105040","DOI":"10.1016\/j.jddst.2023.105040","volume":"89","author":"Banazadeh M.","year":"2023","unstructured":"Banazadeh M.; Behnam B.; Ganjooei N.A.; Gowda B.H.J.; Kesharwani P.; Sahebkar A.; Curcumin-based nanomedicines: A promising avenue for brain neoplasm therapy. J Drug Deliv Sci Technol  2023,89,105040","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-022-01708-4","volume":"22","author":"Zeng L.","year":"2023","unstructured":"Zeng L.; Gowda B.H.J.; Ahmed M.G.; Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol Cancer  2023,22(1),10","journal-title":"Mol Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1208\/s12249-023-02670-0","volume":"24","author":"Hani U.","year":"2023","unstructured":"Hani U.; Gowda B.H.J.; Haider N.; Nanoparticle-based approaches for treatment of hematological malignancies: A comprehensive review. AAPS PharmSciTech  2023,24(8),233","journal-title":"AAPS PharmSciTech"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"103819","DOI":"10.1016\/j.drudis.2023.103819","volume":"29","author":"Khan M.S.","year":"2024","unstructured":"Khan M.S.; Jaswanth Gowda B.H.; Almalki W.H.; Singh T.; Sahebkar A.; Kesharwani P.; Unravelling the potential of mitochondria-targeted liposomes for enhanced cancer treatment. Drug Discov Today  2024,29(1),103819","journal-title":"Drug Discov Today"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2307074","DOI":"10.1002\/adfm.202307074","volume":"16","author":"Gowda B.H.J.","year":"2023","unstructured":"Gowda B.H.J.; Ahmed M.G.; Almoyad M.A.A.; Wahab S.; Almalki W.H.; Kesharwani P.; Nanosponges as an emerging platform for cancer treatment and diagnosis. Adv Funct Mater  2023,16,2307074","journal-title":"Adv Funct Mater"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"116894","DOI":"10.1016\/j.envres.2023.116894","volume":"237","author":"Gowda B.H.J.","year":"2023","unstructured":"Gowda B.H.J.; Ahmed M.G.; Alshehri S.A.; The cubosome-based nanoplatforms in cancer therapy: Seeking new paradigms for cancer theranostics. Environ Res  2023,237(Pt 1),116894","journal-title":"Environ Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"123276","DOI":"10.1016\/j.ijpharm.2023.123276","volume":"643","author":"Khan M.S.","year":"2023","unstructured":"Khan M.S.; Gowda B.H.J.; Nasir N.; Advancements in dextran-based nanocarriers for treatment and imaging of breast cancer. Int J Pharm  2023,643,123276","journal-title":"Int J Pharm"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.3390\/pharmaceutics14081576","volume":"14","author":"Hani U.","year":"2022","unstructured":"Hani U.; Osmani R.A.M.; Yasmin S.; Novel drug delivery systems as an emerging platform for stomach cancer therapy. Pharmaceutics  2022,14(8),1576","journal-title":"Pharmaceutics"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1080\/09205063.2022.2065408","volume":"33","author":"Dubey S.K.","year":"2022","unstructured":"Dubey S.K.; Parab S.; Achalla V.P.K.; Microparticulate and nanotechnology mediated drug delivery system for the delivery of herbal extracts. J Biomater Sci Polym Ed  2022,33(12),1531-1554","journal-title":"J Biomater Sci Polym Ed"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s43094-021-00331-2","volume":"7","author":"Narayana S.","year":"2021","unstructured":"Narayana S.; Ahmed M.G.; Gowda B.H.J.; Recent advances in ocular drug delivery systems and targeting VEGF receptors for management of ocular angiogenesis: A comprehensive review. Fut J Pharmaceut Sci  2021,7(1),186","journal-title":"Fut J Pharmaceut Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"123037","DOI":"10.1016\/j.molliq.2023.123037","volume":"390","author":"Hani U.","year":"2023","unstructured":"Hani U.; Jaswanth Gowda B.H.; Siddiqua A.; Herbal approach for treatment of cancer using curcumin as an anticancer agent: A review on novel drug delivery systems. J Mol Liq  2023,390,123037","journal-title":"J Mol Liq"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"127143","DOI":"10.1016\/j.ijbiomac.2023.127143","volume":"253","author":"Mohanto S.","year":"2023","unstructured":"Mohanto S.; Narayana S.; Merai K.P.; Advancements in gelatin-based hydrogel systems for biomedical applications: A state-of-the-art review. Int J Biol Macromol  2023,253(Pt 5),127143","journal-title":"Int J Biol Macromol"},{"key":"ref=19","first-page":"654","volume":"14","author":"Sanjana A.","year":"2022","unstructured":"Sanjana A.; Ahmed M.G.; Gowda B.H.J.; Surya S.; Formulation and characteristic evaluation of tacrolimus cubosomal gel for vitiligo. J Dispers Sci Technol  2022,14,654","journal-title":"J Dispers Sci Technol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/molecules25010112","volume":"25","author":"Bayda S.","year":"2019","unstructured":"Bayda S.; Adeel M.; Tuccinardi T.; Cordani M.; Rizzolio F.; The history of nanoscience and nanotechnology: From chemical-physical applications to nanomedicine. Molecules  2019,25(1),112-120","journal-title":"Molecules"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/291013","volume":"2014","author":"Jiao T.","year":"2014","unstructured":"Jiao T.; Yan X.; Balan L.; Stepanov A.L.; Chen X.; Hu M.Z.; Chemical functionalization, self-assembly, and applications of nanomaterials and nanocomposites. J Nanomater  2014,2014,1-2","journal-title":"J Nanomater"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/2231-4040.82950","volume":"2","author":"Agrawal Y.K.","year":"2011","unstructured":"Agrawal Y.K.; Patel V.R.; Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res  2011,2(2),81-87","journal-title":"J Adv Pharm Technol Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.3390\/nano12183226","volume":"12","author":"Harish V.","year":"2022","unstructured":"Harish V.; Ansari M.M.; Tewari D.; Nanoparticle and nanostructure synthesis and controlled growth methods. Nanomaterials  2022,12(18),3226-2231","journal-title":"Nanomaterials"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/pr8080947","volume":"8","author":"Kuriganova A.","year":"2020","unstructured":"Kuriganova A.; Faddeev N.; Gorshenkov M.; Kuznetsov D.; Leontyev I.; Smirnova N.; A comparison of &#x201C;Bottom-Up&#x201D; and &#x201C;Top-Down&#x201D; approaches to the synthesis of Pt\/C electrocatalysts. Processes  2020,8(8),947-953","journal-title":"Processes"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.chphi.2023.100355","volume":"7","author":"Tejashwini D.M.","year":"2023","unstructured":"Tejashwini D.M.; Harini H.V.; Nagaswarupa H.P.; Naik R.; Deshmukh V.V.; Basavaraju N.; An in-depth exploration of eco-friendly synthesis methods for metal oxide nanoparticles and their role in photocatalysis for industrial dye degradation. Chemical Physics Impact  2023,7,100355","journal-title":"Chemical Physics Impact"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.rechem.2022.100633","volume":"4","author":"Ahire S.A.","year":"2022","unstructured":"Ahire S.A.; Bachhav A.A.; Pawar T.B.; Jagdale B.S.; Patil A.V.; Koli P.B.; The Augmentation of nanotechnology era: A concise review on fundamental concepts of nanotechnology and applications in material science and technology. Results Chem  2022,4,100633","journal-title":"Results Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"135148","DOI":"10.1016\/j.molstruc.2023.135148","volume":"1281","author":"El-Khawaga A.M.","year":"2023","unstructured":"El-Khawaga A.M.; Zidan A.; El-Mageed A.I.A.A.; Preparation methods of different nanomaterials for various potential applications: A review. J Mol Struct  2023,1281,135148","journal-title":"J Mol Struct"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e24717","DOI":"10.4161\/biom.24717","volume":"3","author":"Bhat S.","year":"2013","unstructured":"Bhat S.; Kumar A.; Biomaterials and bioengineering tomorrow\u2019s healthcare. Biomatter  2013,3(3),e24717","journal-title":"Biomatter"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"14444","DOI":"10.1073\/pnas.1516247112","volume":"112","author":"Tibbitt M.W.","year":"2015","unstructured":"Tibbitt M.W.; Rodell C.B.; Burdick J.A.; Anseth K.S.; Progress in material design for biomedical applications. Proc Natl Acad Sci  2015,112(47),14444-14451","journal-title":"Proc Natl Acad Sci"},{"key":"ref=30","first-page":"504","volume":"40","author":"DeMaagd G.","year":"2015","unstructured":"DeMaagd G.; Philip A.; Parkinson\u2019s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation and diagnosis. PandT  2015,40(8),504-532","journal-title":"PandT"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"DeTure M.A.","year":"2019","unstructured":"DeTure M.A.; Dickson D.W.; The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener  2019,14(1),32-40","journal-title":"Mol Neurodegener"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"Mitchell M.J.","year":"2021","unstructured":"Mitchell M.J.; Billingsley M.M.; Haley R.M.; Wechsler M.E.; Peppas N.A.; Langer R.; Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov  2021,20(2),101-124","journal-title":"Nat Rev Drug Discov"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"11654","DOI":"10.3390\/ijms222111654","volume":"22","author":"Pinheiro R.G.R.","year":"2021","unstructured":"Pinheiro R.G.R.; Coutinho A.J.; Pinheiro M.; Neves A.R.; Nanoparticles for targeted brain drug delivery: What do we know? Int J Mol Sci  2021,22(21),11654","journal-title":"Int J Mol Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"112999","DOI":"10.1016\/j.colsurfb.2022.112999","volume":"221","author":"Teixeira M.I.","year":"2023","unstructured":"Teixeira M.I.; Lopes C.M.; Amaral M.H.; Costa P.C.; Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases. Colloids Surf B Biointerfaces  2023,221,112999","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.7150\/thno.21254","volume":"8","author":"Dong X.","year":"2018","unstructured":"Dong X.; Current strategies for brain drug delivery. Theranostics  2018,8(6),1481-1493","journal-title":"Theranostics"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.3390\/polym15092196","volume":"15","author":"Duan L.","year":"2023","unstructured":"Duan L.; Li X.; Ji R.; Nanoparticle-based drug delivery dystems: An inspiring therapeutic strategy for neurodegenerative diseases. Polymers  2023,15(9),2196","journal-title":"Polymers"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.addr.2018.10.011","volume":"148","author":"Kevadiya B.D.","year":"2019","unstructured":"Kevadiya B.D.; Ottemann B.M.; Thomas M.B.; Neurotheranostics as personalized medicines. Adv Drug Deliv Rev  2019,148,252-289","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"17014","DOI":"10.1038\/natrevmats.2017.14","volume":"2","author":"Park S.","year":"2017","unstructured":"Park S.; Aalipour A.; Vermesh O.; Yu J.H.; Gambhir S.S.; Towards clinically translatable in vivo nanodiagnostics. Nat Rev Mater  2017,2(5),17014","journal-title":"Nat Rev Mater"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s10311-021-01342-4","volume":"20","author":"Sridhar A.","year":"2022","unstructured":"Sridhar A.; Kapoor A.; Kumar P.S.; Ponnuchamy M.; Sivasamy B.; Vo D.V.N.; Lab-on-a-chip technologies for food safety, processing, and packaging applications: A review. Environ Chem Lett  2022,20(1),901-927","journal-title":"Environ Chem Lett"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"10971","DOI":"10.1021\/acs.nanolett.3c03222","volume":"23","author":"Tracy G.C.","year":"2023","unstructured":"Tracy G.C.; Huang K.Y.; Hong Y.T.; Intracerebral nanoparticle transport facilitated by alzheimer pathology and age. Nano Lett  2023,23(23),10971-10982","journal-title":"Nano Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"eadi1617","DOI":"10.1126\/scitranslmed.adi1617","volume":"15","author":"Khang M","year":"2023","unstructured":"Khang M; Lee JH; Lee T; Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma. Sci Transl Med  2023,15(720),eadi1617","journal-title":"Sci Transl Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41551-022-00965-4","volume":"7","author":"Kim T.","year":"2022","unstructured":"Kim T.; Kim H.J.; Choi W.; Deep brain stimulation by blood\u2013brain-barrier-crossing piezoelectric nanoparticles generating current and nitric oxide under focused ultrasound. Nat Biomed Eng  2022,7(2),149-163","journal-title":"Nat Biomed Eng"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"121690","DOI":"10.1016\/j.biomaterials.2022.121690","volume":"288","author":"Zhong G.","year":"2022","unstructured":"Zhong G.; Long H.; Zhou T.; Blood-brain barrier Permeable nanoparticles for Alzheimer\u2019s disease treatment by selective mitophagy of microglia. Biomaterials  2022,288,121690","journal-title":"Biomaterials"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5550938","volume":"2021","author":"Ling T.S.","year":"2021","unstructured":"Ling T.S.; Chandrasegaran S.; Xuan L.Z.; The potential benefits of nanotechnology in treating Alzheimer\u2019s disease. BioMed Res Int  2021,2021,1-9","journal-title":"BioMed Res Int"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/biomedicines11061752","volume":"11","author":"Mir Najib Ullah S.N.","year":"2023","unstructured":"Mir Najib Ullah S.N.; Afzal O.; Altamimi A.S.A.; Nanomedicine in the management of Alzheimer\u2019s Disease: State-of-the-art. Biomedicines  2023,11(6),1752","journal-title":"Biomedicines"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1042986","DOI":"10.3389\/fbioe.2022.1042986","volume":"10","author":"Cao Y.","year":"2022","unstructured":"Cao Y.; Zhang R.; The application of nanotechnology in treatment of Alzheimer\u2019s disease. Front Bioeng Biotechnol  2022,10,1042986","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"130559","DOI":"10.1016\/j.bbagen.2024.130559","author":"Panghal A.","year":"2024","unstructured":"Panghal A.; Flora S.J.S.; Nanotechnology in the diagnostic and therapy for Alzheimer's disease. Biochimica et Biophysica Acta  2024,130559","journal-title":"Biochimica et Biophysica Acta"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2478\/jtim-2021-0054","volume":"10","author":"Gong B.","year":"2023","unstructured":"Gong B.; Zhuang J.; Ji W.; The long and the short of current nanomedicines for treating Alzheimer\u2019s disease. J Transl Int Med  2023,10(4),294-296","journal-title":"J Transl Int Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ncl.2017.01.005","volume":"35","author":"Mendez M.F.","year":"2017","unstructured":"Mendez M.F.; Early-onset Alzheimer disease. Neurol Clin  2017,35(2),263-281","journal-title":"Neurol Clin"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-cellbio-040320-120625","volume":"36","author":"Mallucci G.R.","year":"2020","unstructured":"Mallucci G.R.; Klenerman D.; Rubinsztein D.C.; Developing therapies for neurodegenerative disorders: Insights from protein aggregation and cellular stress responses. Annu Rev Cell Dev Biol  2020,36(1),165-189","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"Hampel H.","year":"2021","unstructured":"Hampel H.; Hardy J.; Blennow K.; The amyloid-&#x3B2; pathway in Alzheimer\u2019s disease. Mol Psychiatry  2021,26(10),5481-5503","journal-title":"Mol Psychiatry"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","volume":"12","author":"Chow V.W.","year":"2010","unstructured":"Chow V.W.; Mattson M.P.; Wong P.C.; Gleichmann M.; An overview of APP processing enzymes and products. Neuromolecular Med  2010,12(1),1-12","journal-title":"Neuromolecular Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/JAD-2010-1221","volume":"19","author":"Murphy M.P.","year":"2010","unstructured":"Murphy M.P.; LeVine H.; Alzheimer\u2019s disease and the amyloid-beta peptide. J Alzheimers Dis  2010,19(1),311-323","journal-title":"J Alzheimers Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1523\/JNEUROSCI.23-01-00029.2003","volume":"23","author":"Matsuoka Y.","year":"2003","unstructured":"Matsuoka Y.; Saito M.; LaFrancois J.; Novel therapeutic approach for the treatment of Alzheimer\u2019s disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci  2003,23(1),29-33","journal-title":"J Neurosci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1016\/j.biomaterials.2010.04.044","volume":"31","author":"Gobbi M.","year":"2010","unstructured":"Gobbi M.; Re F.; Canovi M.; Lipid-based nanoparticles with high binding affinity for amyloid-&#x3B2;1-42 peptide. Biomaterials  2010,31(25),6519-6529","journal-title":"Biomaterials"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"879114","DOI":"10.3389\/fnagi.2022.879114","volume":"14","author":"Chopra H.","year":"2022","unstructured":"Chopra H.; Bibi S.; Singh I.; Nanomedicines in the management of Alzheimer\u2019s disease: Current view and future prospects. Front Aging Neurosci  2022,14,879114","journal-title":"Front Aging Neurosci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.nano.2011.05.009","volume":"7","author":"Bereczki E.","year":"2011","unstructured":"Bereczki E.; Re F.; Masserini M.E.; Winblad B.; Pei J.J.; Liposomes functionalized with acidic lipids rescue A&#x3B2;-induced toxicity in murine neuroblastoma cells. Nanomedicine  2011,7(5),560-571","journal-title":"Nanomedicine"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1016\/j.biomaterials.2011.04.020","volume":"32","author":"Canovi M.","year":"2011","unstructured":"Canovi M.; Markoutsa E.; Lazar A.N.; The binding affinity of anti-A&#x3B2;1-42 MAb-decorated nanoliposomes to A&#x3B2;1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. Biomaterials  2011,32(23),5489-5497","journal-title":"Biomaterials"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1166\/jnn.2007.330","volume":"7","author":"Podolski I.Y.","year":"2007","unstructured":"Podolski I.Y.; Podlubnaya Z.A.; Kosenko E.A.; Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. J Nanosci Nanotechnol  2007,7(4),1479-1485","journal-title":"J Nanosci Nanotechnol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0079-6123(08)80005-2","volume":"180","author":"Liu G.","year":"2009","unstructured":"Liu G.; Men P.; Perry G.; Smith M.A.; Development of iron chelator\u2013nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Prog Brain Res  2009,180,97-108","journal-title":"Prog Brain Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neulet.2009.03.064","volume":"455","author":"Liu G.","year":"2009","unstructured":"Liu G.; Men P.; Kudo W.; Perry G.; Smith M.A.; Nanoparticle\u2013chelator conjugates as inhibitors of amyloid-&#x3B2; aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease. Neurosci Lett  2009,455(3),187-190","journal-title":"Neurosci Lett"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1039\/c3dt50406a","volume":"42","author":"Nunes A.","year":"2013","unstructured":"Nunes A.; Marques S.M.; Quintanova C.; Multifunctional iron-chelators with protective roles against neurodegenerative diseases. Dalton Trans  2013,42(17),6058-6073","journal-title":"Dalton Trans"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1471-4159.2005.03340.x","volume":"95","author":"Zheng H.","year":"2005","unstructured":"Zheng H.; Gal S.; Weiner L.M.; Novel multifunctional neuroprotective iron chelator\u2010monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem  2005,95(1),68-78","journal-title":"J Neurochem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neulet.2006.07.020","volume":"406","author":"Liu G.","year":"2006","unstructured":"Liu G.; Men P.; Harris P.L.R.; Rolston R.K.; Perry G.; Smith M.A.; Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett  2006,406(3),189-193","journal-title":"Neurosci Lett"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"14470","DOI":"10.1021\/acs.jmedchem.0c01480","volume":"63","author":"Jiang X.","year":"2020","unstructured":"Jiang X.; Zhou T.; Bai R.; Xie Y.; Hydroxypyridinone-based iron chelators with broad-ranging biological activities. J Med Chem  2020,63(23),14470-14501","journal-title":"J Med Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/3534570","volume":"2020","author":"Pichla M.","year":"2020","unstructured":"Pichla M.; Bartosz G.; Sadowska-Bartosz I.; The antiaggregative and antiamyloidogenic properties of nanoparticles: A promising tool for the treatment and diagnostics of neurodegenerative diseases. Oxid Med Cell Longev  2020,2020,1-11","journal-title":"Oxid Med Cell Longev"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.2147\/IJN.S305851","volume":"16","author":"Cunha S.","year":"2021","unstructured":"Cunha S.; Forbes B.; Sousa Lobo J.M.; Silva A.C.; Improving drug delivery for Alzheimer\u2019s disease through nose-to-brain delivery using nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ hydrogels. Int J Nanomedicine  2021,16,4373-4390","journal-title":"Int J Nanomedicine"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/ph11040109","volume":"11","author":"Nu&#xF1;ez M.","year":"2018","unstructured":"Nu&#xF1;ez M.; Chana-Cuevas P.; New Perspectives in iron chelation therapy for the treatment of neurodegenerative diseases. Pharmaceuticals  2018,11(4),109","journal-title":"Pharmaceuticals"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejpb.2008.03.009","volume":"70","author":"Wilson B.","year":"2008","unstructured":"Wilson B.; Samanta M.; Santhi K.; Kumar K.; Paramakrishnan N.; Suresh B.; Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm  2008,70(1),75-84","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","volume":"337","author":"McLachlan D.","year":"1991","unstructured":"McLachlan D.; Dalton A.J.; Kruck T.P.; Intramuscular desferrioxamine in patients with Alzheimer\u2019s disease. Lancet  1991,337(8753),1304-1308","journal-title":"Lancet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/1871527315666160202124518","volume":"15","author":"Khan T.A.","year":"2016","unstructured":"Khan T.A.; Hassan I.; Ahmad A.; Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders. CNS Neurol Disord Drug Targets  2016,15(3),310-320","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1073\/pnas.0409336102","volume":"102","author":"Georganopoulou D.G.","year":"2005","unstructured":"Georganopoulou D.G.; Chang L.; Nam J.M.; Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer\u2019s disease. Proc Natl Acad Sci  2005,102(7),2273-2276","journal-title":"Proc Natl Acad Sci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"163039","DOI":"10.1016\/j.ijleo.2019.163039","volume":"194","author":"Luo D.","year":"2019","unstructured":"Luo D.; Shi B.; Wang J.; Qian L.; Qin Y.; Particle diameter distribution and number concentration measurement of Au nanospheres solution and its photothermal temperature properties. Optik  2019,194,163039","journal-title":"Optik"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"118174","DOI":"10.1016\/j.saa.2020.118174","volume":"232","author":"Zhang Z.H.","year":"2020","unstructured":"Zhang Z.H.; Lei K.N.; Li C.N.; Luo Y.H.; Jiang Z.L.; A new and facile nanosilver SPR colored method for ultratrace arsenic based on aptamer regulation of Au-doped carbon dot catalytic amplification. Spectrochim Acta A Mol Biomol Spectrosc  2020,232,118174","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"105513","DOI":"10.1016\/j.jece.2021.105513","volume":"9","author":"Jalilian R.","year":"2021","unstructured":"Jalilian R.; Ezzatzadeh E.; Taheri A.; A novel self-assembled gold nanoparticles-molecularly imprinted modified carbon ionic liquid electrode with high sensitivity and selectivity for the rapid determination of bisphenol A leached from plastic containers. J Environ Chem Eng  2021,9(4),105513","journal-title":"J Environ Chem Eng"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.talanta.2011.12.002","volume":"89","author":"Yang L.","year":"2012","unstructured":"Yang L.; Liu S.; Zhang Q.; Li F.; Simultaneous electrochemical determination of dopamine and ascorbic acid using AuNPs@polyaniline core-shell nanocomposites modified electrode. Talanta  2012,89,136-141","journal-title":"Talanta"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.sab.2016.04.009","volume":"122","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; He M.; Chen B.; Hu B.; Ultra-trace determination of gold nanoparticles in environmental water by surfactant assisted dispersive liquid liquid microextraction coupled with electrothermal vaporization-inductively coupled plasma - mass spectrometry. Spectrochim Acta B At Spectrosc  2016,122,94-102","journal-title":"Spectrochim Acta B At Spectrosc"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ab.2008.11.043","volume":"386","author":"Kannan P.","year":"2009","unstructured":"Kannan P.; John S.A.; Determination of nanomolar uric and ascorbic acids using enlarged gold nanoparticles modified electrode. Anal Biochem  2009,386(1),65-72","journal-title":"Anal Biochem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00604-017-2122-6","volume":"184","author":"Gong L.","year":"2017","unstructured":"Gong L.; Du B.; Pan L.; Colorimetric aggregation assay for arsenic(III) using gold nanoparticles. Mikrochim Acta  2017,184(4),1185-1190","journal-title":"Mikrochim Acta"},{"key":"ref=80","first-page":"903","volume":"35","author":"Feng L.","year":"2010","unstructured":"Feng L.; Li S.; Xiao B.; Chen S.; Liu R.; Zhang Y.; Fluorescence imaging of APP in Alzheimer\u2019s disease with quantum dot or Cy3: A comparative study. Zhong Nan Da Xue Xue Bao Yi Xue Ban  2010,35(9),903-909","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.neuroimage.2011.01.023","volume":"55","author":"Yang J.","year":"2011","unstructured":"Yang J.; Wadghiri Y.Z.; Hoang D.M.; Detection of amyloid in Alzheimer\u2019s disease transgenic mice using magnetic resonance microimaging. Neuroimage  2011,55,1600-1610","journal-title":"Neuroimage"},{"key":"ref=82","first-page":"481031","volume":"2009","author":"Roney C.A.","year":"2010","unstructured":"Roney C.A.; Arora V.; Kulkarni P.V.; Antich P.P.; Bonte F.J.; Nanoparticulate radiolabelled quinolines detect amyloid plaques in mouse models of Alzheimer\u2019s disease. Int J Alzheimers Dis  2010,2009,481031","journal-title":"Int J Alzheimers Dis"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/YCO.0000000000000310","volume":"30","author":"Ansari S.A.","year":"2017","unstructured":"Ansari S.A.; Satar R.; Perveen A.; Ashraf G.M.; Current opinion in Alzheimer\u2019s disease therapy by nanotechnology-based approaches. Curr Opin Psychiatry  2017,30(2),128-135","journal-title":"Curr Opin Psychiatry"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2174\/1389200219666180305144143","volume":"19","author":"Azhar A.","year":"2018","unstructured":"Azhar A.; Ashraf G.M.; Zia Q.; Frontier view on nanotechnological strategies for neuro-therapy. Curr Drug Metab  2018,19(7),596-604","journal-title":"Curr Drug Metab"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"055","DOI":"10.1385\/JMN:24:1:055","volume":"24","author":"Wang Y","year":"2004","unstructured":"Wang Y; Klunk WE; Debnath ML; Development of a PET\/SPECT agent for amyloid imaging in Alzheimer\u2019s disease. J Mol Neurosci  2004,24(1),055-62","journal-title":"J Mol Neurosci"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.brainres.2004.08.004","volume":"1025","author":"Kung M.P.","year":"2004","unstructured":"Kung M.P.; Hou C.; Zhuang Z.P.; Skovronsky D.; Kung H.F.; Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer\u2019s disease. Brain Res  2004,1025(1-2),98-105","journal-title":"Brain Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1021\/acsmedchemlett.9b00456","volume":"11","author":"Watanabe H.","year":"2020","unstructured":"Watanabe H.; Tatsumi H.; Kaide S.; Shimizu Y.; Iikuni S.; Ono M.; Structure-activity relationships of radioiodinated 6,5,6-tricyclic compounds for the development of tau imaging probes. ACS Med Chem Lett  2020,11(2),120-126","journal-title":"ACS Med Chem Lett"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1021\/acs.molpharmaceut.7b01070","volume":"15","author":"Chauhan K.","year":"2018","unstructured":"Chauhan K.; Tiwari A.K.; Chadha N.; Kaul A.; Singh A.K.; Datta A.; Chalcone based homodimeric PET agent, 11C-(Chal)2DEA-Me, for beta amyloid imaging: Synthesis and bioevaluation. Mol Pharm  2018,15(4),1515-1525","journal-title":"Mol Pharm"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"115884","DOI":"10.1016\/j.bmc.2020.115884","volume":"29","author":"Li Y.","year":"2021","unstructured":"Li Y.; Zhou K.; Guo W.; Cui M.; 18F-labeled 2-phenylbenzoheterocycles with chiral dihydroxyl side chains as &#x3B2;-amyloid imaging probes. Bioorg Med Chem  2021,29,115884","journal-title":"Bioorg Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"26010","DOI":"10.1117\/1.JNP.15.026010","volume":"15","author":"Tepper M.","year":"2021","unstructured":"Tepper M.; Eravuchira P.J.; Gabay B.; Sharabani-Yosef O.; Gannot I.; Nanoparticles targeting amyloid deposits: A potential contrast agent for diagnosis and treatment. J Nanophotonics  2021,15(2),26010-26018","journal-title":"J Nanophotonics"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2174\/1568026616666161222121229","volume":"17","author":"Bhat S.","year":"2017","unstructured":"Bhat S.; Kamal M.; Yarla N.; Ashraf G.; Synopsis on management strategies for neurodegenerative disorders: Challenges from bench to bedside in successful drug discovery and development. Curr Top Med Chem  2017,17(12),1371-1378","journal-title":"Curr Top Med Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"Outeiro T.F.","year":"2019","unstructured":"Outeiro T.F.; Koss D.J.; Erskine D.; Dementia with Lewy bodies: An update and outlook. Mol Neurodegener  2019,14(1),5","journal-title":"Mol Neurodegener"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"12116","DOI":"10.3390\/ijms241512116","volume":"24","author":"Loveland P.M.","year":"2023","unstructured":"Loveland P.M.; Yu J.J.; Churilov L.; Yassi N.; Watson R.; Investigation of inflammation in Lewy body dementia: A systematic scoping review. Int J Mol Sci  2023,24(15),12116","journal-title":"Int J Mol Sci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/cells12182283","volume":"12","author":"Amin J.","year":"2023","unstructured":"Amin J.; Gee C.; Stowell K.; Coulthard D.; Boche D.; Lymphocytes and their potential role in dementia with Lewy bodies. Cells  2023,12(18),2283","journal-title":"Cells"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/brainsci12020148","volume":"12","author":"Vatter S.","year":"2022","unstructured":"Vatter S.; Leroi I.; Resilience in people with Lewy body disorders and their care partners: Association with mental health, relationship satisfaction, and care burden. Brain Sci  2022,12(2),148","journal-title":"Brain Sci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/WCO.0000000000001173","volume":"36","author":"Gibson L.L.","year":"2023","unstructured":"Gibson L.L.; Abdelnour C.; Chong J.; Ballard C.; Aarsland D.; Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers. Curr Opin Neurol  2023,36(4),264-275","journal-title":"Curr Opin Neurol"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1016\/j.neuron.2023.11.020","volume":"111","author":"Leonardo A.","year":"2023","unstructured":"Leonardo A.; Serine-129 phosphorylation of &#x3B1;-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function. Neuron  2023,111,4006","journal-title":"Neuron"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"102793","DOI":"10.1016\/j.jddst.2021.102793","volume":"66","author":"Shankar J.","year":"2021","unstructured":"Shankar J.; Geetha K.M.; Wilson B.; Potential applications of nanomedicine for treating Parkinson\u2019s disease. J Drug Deliv Sci Technol  2021,66,102793","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"42045","DOI":"10.1021\/acsomega.3c04862","volume":"8","author":"Burns J.","year":"2023","unstructured":"Burns J.; Buck A.C.; D\u2019 Souza S.; Dube A.; Bardien S.; Nanophytomedicines as therapeutic agents for Parkinson\u2019s disease. ACS Omega  2023,8(45),42045-42061","journal-title":"ACS Omega"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s13205-023-03553-8","volume":"13","author":"Adam H","year":"2023","unstructured":"Adam H; Gopinath SCB; Md Arshad MK; An update on pathogenesis and clinical scenario for Parkinson's disease: diagnosis and treatment. 3 Biotech  2023,13,142","journal-title":"3 Biotech"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"672594","DOI":"10.3389\/fbioe.2021.672594","volume":"9","author":"Li A.","year":"2021","unstructured":"Li A.; Tyson J.; Patel S.; Emerging nanotechnology for treatment of Alzheimer\u2019s and Parkinson\u2019s disease. Front Bioeng Biotechnol  2021,9,672594","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jconrel.2023.06.026","volume":"360","author":"van Vliet E.F.","year":"2023","unstructured":"van Vliet E.F.; Knol M.J.; Schiffelers R.M.; Caiazzo M.; Fens M.H.A.M.; Levodopa-loaded nanoparticles for the treatment of Parkinson\u2019s disease. J Control Release  2023,360,212-224","journal-title":"J Control Release"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"17581","DOI":"10.1021\/acsanm.3c02749","volume":"6","author":"Kal&#x10D;ec N.","year":"2023","unstructured":"Kal&#x10D;ec N.; Perani\u0107 N.; Mami\u0107 I.; Selenium nanoparticles as potential drug-delivery systems for the treatment of Parkinson\u2019s disease. ACS Appl Nano Mater  2023,6(19),17581-17592","journal-title":"ACS Appl Nano Mater"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3390\/ma16020699","volume":"16","author":"Ashraf H.","year":"2023","unstructured":"Ashraf H.; Cossu D.; Ruberto S.; Latent potential of multifunctional selenium nanoparticles in neurological diseases and altered gut microbiota. Materials  2023,16(2),699","journal-title":"Materials"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"20230158","DOI":"10.1515\/ntrev-2023-0158","volume":"12","author":"Guo S.","year":"2023","unstructured":"Guo S.; Yi C-X.; Cell type-targeting nanoparticles in treating central nervous system diseases: Challenges and hopes. Nanotechnol Rev  2023,12(1),20230158","journal-title":"Nanotechnol Rev"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4252\/wjsc.v15.i7.687","volume":"15","author":"Oz T.","year":"2023","unstructured":"Oz T.; Kaushik A.; Kujawska M.; Neural stem cells for Parkinson\u2019s disease management: Challenges, nanobased support, and prospects. World J Stem Cells  2023,15(7),687-700","journal-title":"World J Stem Cells"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/archneur.64.1.137","volume":"64","author":"Linazasoro G.","year":"2007","unstructured":"Linazasoro G.; Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial. Arch Neurol  2007,64(1),137-140","journal-title":"Arch Neurol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4103\/aian.AIAN_169_18","volume":"21","author":"Bhalsing K.S.","year":"2018","unstructured":"Bhalsing K.S.; Abbas M.M.; Tan L.C.S.; Role of physical activity in Parkinson\u2019s disease. Ann Indian Acad Neurol  2018,21(4),242-249","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"Connolly B.S.","year":"2014","unstructured":"Connolly B.S.; Lang A.E.; Pharmacological treatment of Parkinson disease: A review. JAMA  2014,311(16),1670-1683","journal-title":"JAMA"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijpharm.2011.07.036","volume":"419","author":"Trapani A.","year":"2011","unstructured":"Trapani A.; De Giglio E.; Cafagna D.; Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int J Pharm  2011,419(1-2),296-307","journal-title":"Int J Pharm"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1056\/NEJMct0800326","volume":"359","author":"LeWitt P.A.","year":"2008","unstructured":"LeWitt P.A.; Levodopa for the treatment of Parkinson\u2019s disease. N Engl J Med  2008,359(23),2468-2476","journal-title":"N Engl J Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijbiomac.2017.12.056","volume":"109","author":"Raj R.","year":"2018","unstructured":"Raj R.; Wairkar S.; Sridhar V.; Gaud R.; Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol  2018,109,27-35","journal-title":"Int J Biol Macromol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2009.09.032","volume":"290","author":"Huang R.","year":"2010","unstructured":"Huang R.; Ke W.; Liu Y.; Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci  2010,290(1-2),123-130","journal-title":"J Neurol Sci"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/mds.20276","volume":"20","author":"Katzenschlager R.","year":"2005","unstructured":"Katzenschlager R.; Hughes A.; Evans A.; Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson\u2019s disease: A prospective study using single\u2010dose challenges. Mov Disord  2005,20(2),151-157","journal-title":"Mov Disord"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","volume":"64","author":"Nyholm D.","year":"2005","unstructured":"Nyholm D.; Nilsson Remahl A.I.M.; Dizdar N.; Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology  2005,64(2),216-223","journal-title":"Neurology"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/jgm.1152","volume":"10","author":"Xia C.F.","year":"2008","unstructured":"Xia C.F.; Boado R.J.; Zhang Y.; Chu C.; Pardridge W.M.; Intravenous glial\u2010derived neurotrophic factor gene therapy of experimental Parkinson\u2019s disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J Gene Med  2008,10(3),306-315","journal-title":"J Gene Med"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jconrel.2011.02.022","volume":"151","author":"Wen Z.","year":"2011","unstructured":"Wen Z.; Yan Z.; Hu K.; Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson\u2019s disease following intranasal administration. J Control Release  2011,151(2),131-138","journal-title":"J Control Release"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1602\/neurorx.2.1.108","volume":"2","author":"Olivier J.C.","year":"2005","unstructured":"Olivier J.C.; Drug transport to brain with targeted nanoparticles. NeuroRx  2005,2(1),108-119","journal-title":"NeuroRx"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1126\/science.1120027","volume":"311","author":"Wightman R.M.","year":"2006","unstructured":"Wightman R.M.; Detection technologies. Probing cellular chemistry in biological systems with microelectrodes. Science  2006,311(5767),1570-1574","journal-title":"Science"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.parkreldis.2007.11.012","volume":"14","author":"Linazasoro G.","year":"2008","unstructured":"Linazasoro G.; Potential applications of nanotechnologies to Parkinson\u2019s disease therapy. Parkinsonism Relat Disord  2008,14(5),383-392","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=121","first-page":"2077","volume":"7","author":"Yang X.","year":"2012","unstructured":"Yang X.; Zheng R.; Cai Y.; Liao M.; Yuan W.; Liu Z.; Controlled-release levodopa methyl ester\/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int J Nanomedicine  2012,7,2077-2086","journal-title":"Int J Nanomedicine"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3109\/1061186X.2015.1020809","volume":"23","author":"Kulkarni A.D.","year":"2015","unstructured":"Kulkarni A.D.; Vanjari Y.H.; Sancheti K.H.; Belgamwar V.S.; Surana S.J.; Pardeshi C.V.; Nanotechnology-mediated nose to brain drug delivery for Parkinson\u2019s disease: A mini review. J Drug Target  2015,23(9),775-788","journal-title":"J Drug Target"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0014-4886(92)90053-S","volume":"115","author":"During M.J.","year":"1992","unstructured":"During M.J.; Freese A.; Deutch A.Y.; Biochemical and behavioral recovery in a rodent model of Parkinson\u2019s disease following stereotactic implantation of dopamine-containing liposomes. Exp Neurol  1992,115(2),193-199","journal-title":"Exp Neurol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijpharm.2009.08.021","volume":"382","author":"Pillay S.","year":"2009","unstructured":"Pillay S.; Pillay V.; Choonara Y.E.; Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Int J Pharm  2009,382(1-2),277-290","journal-title":"Int J Pharm"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/jbm.a.35312","volume":"103","author":"Rashed E.R.","year":"2015","unstructured":"Rashed E.R.; Abd El-Rehim H.A.; El-Ghazaly M.A.; Potential efficacy of dopamine loaded\u2010PVP\/PAA nanogel in experimental models of Parkinsonism: Possible disease modifying activity. J Biomed Mater Res A  2015,103(5),1713-1720","journal-title":"J Biomed Mater Res A"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3109\/03639045.2013.789051","volume":"40","author":"Sharma S.","year":"2014","unstructured":"Sharma S.; Lohan S.; Murthy R.S.R.; Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm  2014,40(7),869-878","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s00216-006-0314-8","volume":"385","author":"Balasubramanian K.","year":"2006","unstructured":"Balasubramanian K.; Burghard M.; Biosensors based on carbon nanotubes. Anal Bioanal Chem  2006,385(3),452-468","journal-title":"Anal Bioanal Chem"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"14439","DOI":"10.1002\/chem.201001654","volume":"16","author":"An Y.","year":"2010","unstructured":"An Y.; Tang L.; Jiang X.; A photoelectrochemical immunosensor based on Au-doped TiO2 nanotube arrays for the detection of &#x3B1;-synuclein. Chemistry  2010,16(48),14439-14446","journal-title":"Chemistry"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1021\/nn900813b","volume":"3","author":"Neely A.","year":"2009","unstructured":"Neely A.; Perry C.; Varisli B.; Ultrasensitive and highly selective detection of Alzheimer\u2019s disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle. ACS Nano  2009,3(9),2834-2840","journal-title":"ACS Nano"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11481-008-9115-5","volume":"4","author":"Yu J.","year":"2009","unstructured":"Yu J.; Lyubchenko Y.L.; Early stages for Parkinson\u2019s development: Alpha-synuclein misfolding and aggregation. J Neuroimmune Pharmacol  2009,4(1),10-16","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s00216-010-4273-8","volume":"398","author":"Kosicek M.","year":"2010","unstructured":"Kosicek M.; Kirsch S.; Bene R.; Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer\u2019s disease patients-a pilot study. Anal Bioanal Chem  2010,398(7-8),2929-2937","journal-title":"Anal Bioanal Chem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1021\/ac048691v","volume":"77","author":"Baron R.","year":"2005","unstructured":"Baron R.; Zayats M.; Willner I.; Dopamine-, L-DOPA-, adrenaline-, and noradrenaline-induced growth of Au nanoparticles: Assays for the detection of neurotransmitters and of tyrosinase activity. Anal Chem  2005,77(6),1566-1571","journal-title":"Anal Chem"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715273297024240201055550","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/226923\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715273297024240201055550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T07:51:03Z","timestamp":1725609063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/226923\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":132,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715273297024240201055550","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}